Here are three things to know:
1. Through the IPO, the company proposes to raise $8 million by offering 20 million shares at an offer price of $0.40 a share.
2. The company plans to use the proceeds to finalize the development of its CelGro product, a collagen-based scaffold for orthopedic applications as well as expand the reach of its Ortho-ATI and Ortho-ACI products.
3. KTM Capital and Azure Capital will act as lead bookrunners on the offering, while Shaw Stockbroking will act as co-manager.
More Articles on Devices:
5 Key Results: LDR’s Mobi-C Artificial Disc Replacement vs. ACDF
FDA Clears AccelSPINE’s Next Generation Minimally Invasive Spine System
Global Medical Device Market to Grow at 6.2% Annually Until 2018
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
